Literature DB >> 25983080

Development of a prediction model and risk score for procedure-related complications in patients undergoing percutaneous computed tomography-guided lung biopsy.

Michele Anzidei1, Beatrice Sacconi2, Francesco Fraioli3, Luca Saba4, Pierleone Lucatelli1, Alessandro Napoli1, Flavia Longo5, Domenico Vitolo6, Federico Venuta7, Marco Anile7, Daniele Diso7, Mario Bezzi1, Carlo Catalano1.   

Abstract

OBJECTIVES: To propose a risk score predicting the potential occurrence of procedure-related complications in patients undergoing computed tomography (CT)-guided lung biopsy.
METHODS: Institution review board approval was obtained. A total of 342 CT-guided lung biopsies were retrospectively evaluated taking into account procedure-related complications and associated risk factors, including patient gender and age, previous radiation therapy (RT) and/or chemotherapy (CHT), lesion size, depth and location, incomplete pulmonary fissures, associated diffuse lung diseases, previous pneumothorax (PNX), lung volumes, punctured fissures, thoracic access, needle size and operator experience. Complications were assessed on chest X-ray and/or CT scans. Stepwise logistic regression was used to identify risk factors, to evaluate their correlation with procedure-related complications and to calculate models of risk (MoRs).
RESULTS: PNX requiring chest tube placement occurred in 39 patients (11.4%), high-grade pulmonary parenchymal haemorrhage occurred in 62 patients (18.1%) and haemothorax occurred in 12 patients (3.5%). Risk factors increasing the incidence of complications were lesion size (P = 0.01), lesion depth (P = 0.01) and incomplete pulmonary fissures (P = 0.01); previous chemo-radiation therapy was correlated to a lower incidence of complications (P = 0.01). MoR for PNX was as follows: risk base line = 60%; age = +0.15%/year; punctured fissures = +20%; incomplete fissures = +9%; previous CHT/RT = -10%. MoR for parenchymal haemorrhage was as follows: risk base line = 20%, lesion depth = +0.8%/mm; age = +0.25%/year; incomplete fissures = +15%. MoR for haemothorax was as follows: risk base line = 1%; previous PNX = +20%; incomplete fissures = 7%; both previous PNX and incomplete fissures = +67%.
CONCLUSION: This study provides MoRs to predict the risk of complications in patients undergoing CT-guided percutaneous lung biopsies.
© The Author 2015. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  CT-guided lung biopsy; Complications; Lung tumour; Pneumothorax; Risk score

Mesh:

Year:  2015        PMID: 25983080     DOI: 10.1093/ejcts/ezv172

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  10 in total

1.  Diagnostic accuracy and complication rates of percutaneous CT-guided coaxial needle biopsy of pulmonary lesions.

Authors:  Vesna Sarajlic; Sanela Vesnic; Dalma Udovicic-Gagula; Haris Kuric; Okan Akhan
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

2.  Hemoptysis associated with percutaneous transthoracic needle biopsy: Development of critical events checklist and procedure outcomes.

Authors:  Piera C Robson; David O'Connor; Perri Pardini; Terrah F Akard; Mary S Dietrich; Alan Kotin; Alexandra Solomon; Mohit Chawla; Matthew Kennedy; Stephen B Solomon
Journal:  J Radiol Nurs       Date:  2021-05-25

3.  Pulmonary emphysema is a predictor of pneumothorax after CT-guided transthoracic pulmonary biopsies of pulmonary nodules.

Authors:  Derik Lendeckel; Marie-Luise Kromrey; Till Ittermann; Sophia Schäfer; Birger Mensel; Jens-Peter Kühn
Journal:  PLoS One       Date:  2017-06-02       Impact factor: 3.240

4.  Open Bronchus Sign on CT: A Risk Factor for Hemoptysis after Percutaneous Transthoracic Biopsy.

Authors:  Hyungjin Kim; Chang Min Park; Soon Ho Yoon; Eui Jin Hwang; Jong Hyuk Lee; Su Yeon Ahn; Jin Mo Goo
Journal:  Korean J Radiol       Date:  2018-08-06       Impact factor: 3.500

5.  Complications of CT-guided lung biopsy with a non-coaxial semi-automated 18 gauge biopsy system: Frequency, severity and risk factors.

Authors:  Amany Saad Elshafee; Annika Karch; Kristina I Ringe; Hoen-Oh Shin; Hans-Jürgen Raatschen; Nermin Yehia Soliman; Frank Wacker; Jens Vogel-Claussen
Journal:  PLoS One       Date:  2019-03-18       Impact factor: 3.240

6.  Three-dimensionally printed navigational template: a promising guiding approach for lung biopsy.

Authors:  Haoran E; Jiafei Chen; Weiyan Sun; Yikai Zhang; Shengxiang Ren; Jingyun Shi; Yaofeng Wen; Chunxia Su; Jian Ni; Lei Zhang; Yayi He; Bin Chen; Roberto F Casal; Fayez Kheir; Tsukasa Ishiwata; Jie Zhang; Deping Zhao; Chang Chen
Journal:  Transl Lung Cancer Res       Date:  2022-03

7.  Pneumothorax rates in CT-Guided lung biopsies: a comprehensive systematic review and meta-analysis of risk factors.

Authors:  Ya Ruth Huo; Michael Vinchill Chan; Al-Rahim Habib; Isaac Lui; Lloyd Ridley
Journal:  Br J Radiol       Date:  2020-01-03       Impact factor: 3.039

Review 8.  Imaging-guided chest biopsies: techniques and clinical results.

Authors:  Michele Anzidei; Andrea Porfiri; Fabrizio Andrani; Michele Di Martino; Luca Saba; Carlo Catalano; Mario Bezzi
Journal:  Insights Imaging       Date:  2017-06-21

9.  Chinese multidisciplinary expert consensus: Guidelines on percutaneous transthoracic needle biopsy.

Authors:  Zhi Guo; Hong Shi; Wentao Li; Dongmei Lin; Changli Wang; Chen Liu; Min Yuan; Xia Wu; Bin Xiong; Xinhong He; Feng Duan; Jianjun Han; Xueling Yang; Haipeng Yu; Tongguo Si; Linfeng Xu; Wenge Xing; Huang Jinhua; Yingjuan Wang; Hui Xie; Li Cui; Wei Gao; Dongfeng He; Changfu Liu; Zhou Liu; Chunhua Ma; Jie Pan; Haibo Shao; Qiang Tu; Li Yong; Yan Xu; Zhang Weihao; Zou Qiang; Sen Wang
Journal:  Thorac Cancer       Date:  2018-09-17       Impact factor: 3.500

10.  Pneumothorax after percutaneous transthoracic lung biopsy. Non-invasive management in order to avoid unnecessary hospitalizations

Authors:  Francisco Calderon Novoa; Agustin Dietrich; Micaela Raices; Juan Alejandro Montagne; Matias Borensztein; David Smith
Journal:  Rev Fac Cien Med Univ Nac Cordoba       Date:  2021-03-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.